• This record comes from PubMed

Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma

. 2021 Feb ; 47 (Supp. 1) : S33-S44. [epub] 20201009

Status PubMed-not-MEDLINE Language English Country Turkey Media print-electronic

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/pmid33052841

Upper-tract urothelial carcinoma (UTUC) is a rare disease, posing many challenges for the treating physician due to the lack of strong evidence-based recommendations. However, novel molecular discoveries and a better understanding of the clinical behavior of the disease lead to a continuous evolution of therapeutic landscape in UTUC. The aim of the review is to provide a comprehensive update of the current diagnostic modalities and treatment strategies in UTUC with a special focus on recent developments and challenges. A comprehensive literature search including relevant articles up to August 2020 was performed using the MEDLINE/PubMed database. Despite several technological improvements, accurate staging and outcome prediction remain major challenges and hamper appropriate risk stratification. Kidney-sparing surgery can be offered in low risk UTUC; however, physician and patient must be aware of the high rate of recurrence and risk of progression due to tumor biology and understaging. The value and efficacy of intracavitary therapy in patients with UTUC remains unclear due to the lack of high-quality data. In high-risk diseases, radical nephroureterectomy with bladder cuff excision and template lymph node dissection is the standard of care. Perioperative systemic chemotherapy is today accepted as a novel standard for advanced cancers. In metastatic or unresectable disease, the therapeutic landscape is rapidly changing due to several novel agents, such as checkpoint inhibitors. While several diagnostic and treatment challenges remain, progress in endoscopic technology and molecular knowledge have ushered a new age in personalized management of UTUC. Novel accurate molecular and imaging biomarkers are, however, still needed to guide decision making as tissue acquisition remains suboptimal. Next generation sequencing and novel agents are promising to rapidly improve patient outcomes.

See more in PubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. PubMed DOI

Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 2013;189:1214–21. doi: 10.1016/j.juro.2012.05.079. PubMed DOI

Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2015;68:970–7. doi: 10.1016/j.eururo.2015.07.039. PubMed DOI PMC

Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, et al. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017;72:641–9. doi: 10.1016/j.eururo.2017.05.048. PubMed DOI

Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, et al. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. Eur Urol. 2020;78:209–20. doi: 10.1016/j.eururo.2020.05.039. PubMed DOI

Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol. 2012;62:677–84. doi: 10.1016/j.eururo.2012.02.018. PubMed DOI

Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62:100–14. doi: 10.1016/j.eururo.2012.02.030. PubMed DOI

Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol. 2020;38:1165–75. doi: 10.1007/s00345-019-02875-8. PubMed DOI

Rouprêt M, Babjuk M, Burger M, Compérat E, Cowan N, Gontero P, et al. Upper Urinary Tract Urothelial Cell Carcinoma, EAU Guidelines. Edn presented at the EAU Annual Congress; Amsterdam. 2020; Arnhem, The Netherlands: EAU Guidelines Office;

Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, et al. Diagnostic Value of (18)F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2020;3:73–9. doi: 10.1016/j.euo.2019.09.004. PubMed DOI

Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010;57:1072–9. doi: 10.1016/j.eururo.2009.07.002. PubMed DOI

Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol. 2010;58:574–80. doi: 10.1016/j.eururo.2010.07.003. PubMed DOI PMC

Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009;103:307–11. doi: 10.1111/j.1464-410X.2008.08003.x. PubMed DOI

Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol. 2012;61:245–53. doi: 10.1016/j.eururo.2011.09.017. PubMed DOI

Mathieu R, Bensalah K, Lucca I, Mbeutcha A, Roupret M, Shariat SF. Upper urinary tract disease: what we know today and unmet needs. Transl Androl Urol. 2015;4:261–72. PubMed PMC

Rojas CP, Castle SM, Llanos CA, Santos Cortes JA, Bird V, Rodriguez S, et al. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol. 2013;31:1696–700. doi: 10.1016/j.urolonc.2012.05.010. PubMed DOI

Territo A, Foerster B, Shariat SF, Roupret M, Gaya JM, Palou J, et al. Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art. Minerva Urol Nefrol. 2018;70:242–51. PubMed

Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int. 2012;109:77–82. doi: 10.1111/j.1464-410X.2011.10288.x. PubMed DOI PMC

Joseph JP, Potretzke TA, Packiam V, Sharma V, Toussi A, Miest TS, et al. Percutaneous Image-guided Core Needle Biopsy for Upper Tract Urothelial Carcinoma. Urology. 2020;135:95–100. doi: 10.1016/j.urology.2019.10.005. PubMed DOI

Bus MT, de Bruin DM, Faber DJ, Kamphuis GM, Zondervan PJ, Laguna Pes MP, et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol. 2015;29:113–23. doi: 10.1089/end.2014.0551. PubMed DOI

Pradere B, Poulon F, Comperat E, Lucas IT, Bazin D, Doizi S, et al. Two-photon optical imaging, spectral and fluorescence lifetime analysis to discriminate urothelial carcinoma grades. J Biophotonics. 2018;11:e201800065. doi: 10.1002/jbio.201800065. PubMed DOI

Keller EX, Doizi S, Villa L, Traxer O. Which flexible ureteroscope is the best for upper tract urothelial carcinoma treatment? World J Urol. 2019;37:2325–33. doi: 10.1007/s00345-019-02675-0. PubMed DOI

Traxer O, Geavlete B, de Medina SG, Sibony M, Al-Qahtani SM. Narrow-band imaging digital flexible ureteroscopy in detection of upper urinary tract transitional-cell carcinoma: initial experience. J Endourol. 2011;25:19–23. doi: 10.1089/end.2009.0593. PubMed DOI

Kata SG, Aboumarzouk OM, Zreik A, Somani B, Ahmad S, Nabi G, et al. Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour. Photodiagnosis Photodyn Ther. 2016;13:255–60. doi: 10.1016/j.pdpdt.2015.08.002. PubMed DOI

Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011;108:701–5. doi: 10.1111/j.1464-410X.2010.09899.x. PubMed DOI

Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 2006;97:997–1001. doi: 10.1111/j.1464-410X.2006.06036.x. PubMed DOI

Malm C, Grahn A, Jaremko G, Tribukait B, Brehmer M. Diagnostic accuracy of upper tract urothelial carcinoma: how samples are collected matters. Scand J Urol. 2017;51:137–45. doi: 10.1080/21681805.2017.1295102. PubMed DOI

Johannes JR, Nelson E, Bibbo M, Bagley DH. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol. 2010;184:879–82. doi: 10.1016/j.juro.2010.05.023. PubMed DOI

Lodde M, Mian C, Wiener H, Haitel A, Pycha A, Marberger M. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology. 2001;58:362–6. doi: 10.1016/S0090-4295(01)01182-7. PubMed DOI

Marín-Aguilera M, Mengual L, Ribal MJ, Musquera M, Ars E, Villavicencio H, et al. Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol. 2007;51:409–15. doi: 10.1016/j.eururo.2006.08.045. PubMed DOI

Coskuner E, Cevik I, Ozkan A, Dillioglugil O, Akdas A. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors. Int Urol Nephrol. 2012;44:793–8. doi: 10.1007/s11255-012-0144-x. PubMed DOI

Gayed BA, Seideman C, Lotan Y. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol. 2013;190:1181–6. doi: 10.1016/j.juro.2013.03.117. PubMed DOI

D’Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, et al. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019;123:959–67. doi: 10.1111/bju.14673. PubMed DOI PMC

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, et al. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clin Cancer Res. 2019;25:967–76. doi: 10.1158/1078-0432.CCR-18-2039. PubMed DOI PMC

Seisen T, Granger B, Colin P, Léon P, Utard G, Renard-Penna R, et al. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. Eur Urol. 2015;67:1122–33. doi: 10.1016/j.eururo.2014.11.035. PubMed DOI

Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183:68–75. doi: 10.1016/j.juro.2009.08.115. PubMed DOI

Metcalfe MJ, Petros FG, Rao P, Mork ME, Xiao L, Broaddus RR, et al. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol. 2018;199:60–5. doi: 10.1016/j.juro.2017.08.002. PubMed DOI

Pradere B, Lotan Y, Roupret M. Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance. Curr Opin Urol. 2017;27:48–55. doi: 10.1097/MOU.0000000000000340. PubMed DOI

Donahu TF, Bagrodia A, Audenet F, Donoghue MTA, Cha EK, Sfakianos JP, et al. Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precis Oncol. 2018 PO.17.00143. PubMed PMC

Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010;57:575–81. doi: 10.1016/j.eururo.2009.11.035. PubMed DOI

Seitz C, Gupta A, Shariat SF, Matsumoto K, Kassouf W, Walton TJ, et al. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J Urol. 2010;184:1895–900. doi: 10.1016/j.juro.2010.06.106. PubMed DOI

Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol. 2010;57:1064–71. doi: 10.1016/j.eururo.2009.12.029. PubMed DOI

Zamboni S, Foerster B, Abufaraj M, Seisen T, Roupret M, Colin P, et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU Int. 2019;124:738–45. doi: 10.1111/bju.14751. PubMed DOI

Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol. 2013;63:1082–90. doi: 10.1016/j.eururo.2012.06.029. PubMed DOI PMC

Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol. 2012;187:845–51. doi: 10.1016/j.juro.2011.10.158. PubMed DOI

Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, et al. Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 2014;191:316–22. doi: 10.1016/j.juro.2013.09.010. PubMed DOI

Foerster B, Moschini M, Abufaraj M, Soria F, Gust KM, Roupret M, et al. Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2017;15:e1039–e45. doi: 10.1016/j.clgc.2017.06.003. PubMed DOI

Vartolomei MD, Kimura S, Ferro M, Vartolomei L, Foerster B, Abufaraj M, et al. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. World J Urol. 2018;36:1019–29. doi: 10.1007/s00345-018-2235-5. PubMed DOI

D’Andrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, et al. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2019;5:97–103. doi: 10.1016/j.euf.2017.06.011. PubMed DOI

Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, et al. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC) World J Urol. 2017;35:251–9. doi: 10.1007/s00345-016-1871-x. PubMed DOI

Abufaraj M, Moschini M, Soria F, Gust K, Ozsoy M, Mathieu R, et al. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017;35:1073–80. doi: 10.1007/s00345-016-1968-2. PubMed DOI PMC

Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, et al. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. World J Urol. 2017;35:943–9. doi: 10.1007/s00345-016-1946-8. PubMed DOI

Abufaraj M, Kimura S, Haitel A, Iwata T, Isleem U, D’Andrea D, et al. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urol Oncol. 2020;38:685.e17–e25. doi: 10.1016/j.urolonc.2020.03.030. PubMed DOI

Soria F, Giordano A, D’Andrea D, Moschini M, Roupret M, Margulis V, et al. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. Urol Oncol. 2020;38:602.e11–e19. doi: 10.1016/j.urolonc.2020.01.004. PubMed DOI

Petros FG, Qiao W, Singla N, Clinton TN, Robyak H, Raman JD, et al. Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. Urol Oncol. 2019;37:292.e1–e9. doi: 10.1016/j.urolonc.2018.12.002. PubMed DOI

Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol. 2013;189:1662–9. doi: 10.1016/j.juro.2012.10.057. PubMed DOI

Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012;61:818–25. doi: 10.1016/j.eururo.2012.01.021. PubMed DOI

Yates DR, Hupertan V, Colin P, Ouzzane A, Descazeaud A, Long JA, et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram. Br J Cancer. 2012;106:1083–8. doi: 10.1038/bjc.2012.64. PubMed DOI PMC

Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, et al. Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int. 2014;114:733–40. doi: 10.1111/bju.12631. PubMed DOI

Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, et al. Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017;197:580–9. doi: 10.1016/j.juro.2017.02.2259. PubMed DOI

Ku JH, Moon KC, Jung JH, Jeong SH, Kwak C, Kim HH. External validation of an online nomogram in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Br J Cancer. 2013;109:1130–6. doi: 10.1038/bjc.2013.462. PubMed DOI PMC

Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2014;65:210–7. doi: 10.1016/j.eururo.2012.04.052. PubMed DOI

Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol. 2011;60:776–83. doi: 10.1016/j.eururo.2011.07.009. PubMed DOI

Quhal F, Mori K, Sari Motlagh R, Laukhtina E, Pradere B, Roupret M, et al. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25:1037–54. doi: 10.1007/s10147-020-01650-9. PubMed DOI

Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol. 2016;70:1052–68. doi: 10.1016/j.eururo.2016.07.014. PubMed DOI

Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol. 2017;35:355–65. doi: 10.1007/s00345-016-1859-6. PubMed DOI PMC

Verges DP, Lallas CD, Hubosky SG, Bagley DH., Jr Endoscopic Treatment of Upper Tract Urothelial Carcinoma. Curr Urol Rep. 2017;18:31. doi: 10.1007/s11934-017-0675-x. PubMed DOI

Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012;110:614–28. doi: 10.1111/j.1464-410X.2012.11068.x. PubMed DOI

Villa L, Cloutier J, Letendre J, Ploumidis A, Salonia A, Cornu JN, et al. Early repeated ureteroscopy within 6–8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol. 2016;34:1201–6. doi: 10.1007/s00345-015-1753-7. PubMed DOI

Wang JK, Tollefson MK, Krambeck AE, Trost LW, Thompson RH. High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology. 2012;79:615–9. doi: 10.1016/j.urology.2011.11.049. PubMed DOI

Huang Z, Zhang X, Zhang X, Li Q, Liu S, Yu L, et al. Segmental Ureterectomy is Acceptable for High-risk Ureteral Carcinoma Comparing to Radical Nephroureterectomy. J Invest Surg. 2019;32:746–53. doi: 10.1080/08941939.2018.1457192. PubMed DOI

Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009;45:3291–7. doi: 10.1016/j.ejca.2009.06.016. PubMed DOI

Simonato A, Varca V, Gregori A, Benelli A, Ennas M, Lissiani A, et al. Elective segmental ureterectomy for transitional cell carcinoma of the ureter: long-term follow-up in a series of 73 patients. BJU Int. 2012;110:E744–9. doi: 10.1111/j.1464-410X.2012.11554.x. PubMed DOI

Xylinas E, Rouprêt M, Shariat SF. Segmental ureterectomy for upper tract urothelial carcinoma: two procedures with different indications. Urol Oncol. 2013;31:1841–3. doi: 10.1016/j.urolonc.2013.07.009. PubMed DOI

Veccia A, Antonelli A, Checcucci E, Falagario U, Carrieri G, Guruli G, et al. Segmental Ureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis of Comparative Studies. Clin Genitourin Cancer. 2020;18:e10–e20. doi: 10.1016/j.clgc.2019.10.015. PubMed DOI

Lucca I, Klatte T, Rouprêt M, Shariat SF. Kidney-sparing surgery for upper tract urothelial cancer. Curr Opin Urol. 2015;25:100–4. doi: 10.1097/MOU.0000000000000148. PubMed DOI

Foerster B, D’Andrea D, Abufaraj M, Broenimann S, Karakiewicz PI, Rouprêt M, et al. Endocavitary treatment for upper tract uro-thelial carcinoma: A meta-analysis of the current literature. Urol Oncol. 2019;37:430–6. doi: 10.1016/j.urolonc.2019.02.004. PubMed DOI

Kleinmann N, Pierorazio P, Gore J, Shabsigh A, Hu B, Chamie K, et al. Primary chemoablation of low-grade upper tract urothe-lial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020;21:776–85. doi: 10.1016/S1470-2045(20)30147-9. PubMed DOI

Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Ki-kuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224–33. doi: 10.1002/cncr.24135. PubMed DOI

Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, et al. A delay in radical nephroureterectomy can lead to upstag-ing. BJU Int. 2010;105:812–7. doi: 10.1111/j.1464-410X.2009.08821.x. PubMed DOI

Shariat SF, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Ra-man JD, et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int. 2010;105:1672–7. doi: 10.1111/j.1464-410X.2009.09072.x. PubMed DOI

Chromecki TF, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, et al. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World J Urol. 2011;29:473–80. doi: 10.1007/s00345-011-0677-0. PubMed DOI

Liu F, Guo W, Zhou X, Ding Y, Ma Y, Hou Y, et al. Laparoscopic versus open nephroureterectomy for upper urinary tract urothelial carcinoma: A systematic review and meta-analysis. Medicine (Bal-timore) 2018;97:e11954. doi: 10.1097/MD.0000000000011954. PubMed DOI PMC

Simone G, Papalia R, Guaglianone S, Ferriero M, Leonardo C, Forastiere E, et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospec-tive study. Eur Urol. 2009;56:520–6. doi: 10.1016/j.eururo.2009.06.013. PubMed DOI

Favaretto RL, Shariat SF, Chade DC, Godoy G, Kaag M, Cro-nin AM, et al. Comparison between laparoscopic and open radi-cal nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol. 2010;58:645–51. doi: 10.1016/j.eururo.2010.08.005. PubMed DOI PMC

Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, et al. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the Eu-ropean Association of Urology Guidelines Panel on Non-mus-cle-invasive Bladder Cancer. Eur Urol Focus. 2019;5:224–41. doi: 10.1016/j.euf.2017.09.015. PubMed DOI

Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Sun M, Pharand D, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology. 2010;75:118–24. PubMed

Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Ki-kuchi E, et al. The extent of lymphadenectomy seems to be associ-ated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol. 2009;56:512–8. doi: 10.1016/j.eururo.2009.06.004. PubMed DOI

Guo R, Zhu Y, Xiong G, Li X, Zhang K, Zhou L. Role of lymph node dissection in the management of upper tract urothelial carci-nomas: a meta-analysis. BMC Urol. 2018;18:24. doi: 10.1186/s12894-018-0336-5. PubMed DOI PMC

Kondo T, Hara I, Takagi T, Kodama Y, Hashimoto Y, Kobayashi H, et al. Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study. Int J Urol. 2014;21:453–9. doi: 10.1111/iju.12338. PubMed DOI

O’Brien T, Ray E, Singh R, Coker B, Beard R. Prevention of Bladder Tumours after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: A Prospective, Multicentre, Randomised Clini-cal Trial of a Single Postoperative Intravesical Dose of Mitomycin C (the ODMIT-C Trial) Eur Urol. 2011;60:703–10. doi: 10.1016/j.eururo.2011.05.064. PubMed DOI

Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, et al. Prospective Randomized Phase II Trial of a Single Early Intravesi-cal Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial. J Clin Oncol. 2013;31:1422–7. doi: 10.1200/JCO.2012.45.2128. PubMed DOI

Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephro-ureterectomy for primary upper urinary tract urothelial carcino-mas: a systematic review and meta-analysis. Urol Int. 2013;91:291–6. doi: 10.1159/000350508. PubMed DOI

Wu P, Zhu G, Wei D, Liu S, Walsh K, Li D, et al. Prophylactic in-travesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: A systematic review and meta-analysis. J Buon. 2015;20:1229–38. PubMed

Seisen T, Krasnow RE, Bellmunt J, Roupret M, Leow JJ, Lipsitz SR, et al. Effectiveness of Adjuvant Chemotherapy After Radi-cal Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017;35:852–60. doi: 10.1200/JCO.2016.69.4141. PubMed DOI

Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, et al. Adjuvant chemotherapy after radical nephroure-terectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothe-lial Carcinoma Collaboration. BJU Int. 2018;121:252–9. doi: 10.1111/bju.14020. PubMed DOI

Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009;182:900–6. doi: 10.1016/j.juro.2009.05.011. PubMed DOI

Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, et al. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterec-tomy: a retrospective study. BJU Int. 2015;116:72–8. doi: 10.1111/bju.12801. PubMed DOI

Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395:1268–77. doi: 10.1016/S0140-6736(20)30415-3. PubMed DOI PMC

Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterec-tomy. BJU Int. 2013;112:453–61. doi: 10.1111/j.1464-410X.2012.11649.x. PubMed DOI

Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64:2448–58. PubMed

Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50–4. doi: 10.1016/j.ejca.2005.08.032. PubMed DOI

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77. doi: 10.1200/JCO.2000.18.17.3068. PubMed DOI

Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107–13. doi: 10.1200/JCO.2011.38.6979. PubMed DOI PMC

Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92. doi: 10.1016/S1470-2045(17)30616-2. PubMed DOI

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76. doi: 10.1016/S0140-6736(16)32455-2. PubMed DOI PMC

De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191–9. doi: 10.1200/JCO.2011.37.3571. PubMed DOI PMC

Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23:406–10. doi: 10.1093/annonc/mdr156. PubMed DOI

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376:1015–26. doi: 10.1056/NEJMoa1613683. PubMed DOI PMC

Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–57. doi: 10.1016/S0140-6736(17)33297-X. PubMed DOI

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22. doi: 10.1016/S1470-2045(17)30065-7. PubMed DOI

Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, et al. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol. 2019;37:1608–16. doi: 10.1200/JCO.19.00538. PubMed DOI PMC

Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61. doi: 10.1200/JCO.2008.20.5534. PubMed DOI

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381:338–48. doi: 10.1056/NEJMoa1817323. PubMed DOI

Find record

Citation metrics

Archiving options